The Journal of Experimental Medicine
ELISpot, FluoroSpot and ELISA kits from Mabtech
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online
doi:10.1084/jem.20082311
The Journal of Experimental Medicine, Vol. 206, No. 5, 1073-1087
The Rockefeller University Press, 0022-1007 $30.00
© Sellars et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 7130K)
Right arrow PDF+supp data (16094K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sellars, M.
Right arrow Articles by Chan, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sellars, M.
Right arrow Articles by Chan, S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Ikaros controls isotype selection during immunoglobulin class switch recombination

MacLean Sellars1,3,4,5,6, Bernardo Reina-San-Martin2,3,4,5,6, Philippe Kastner1,3,4,5,6, and Susan Chan1,3,4,5,6

1 Laboratory of Hematopoiesis and Leukemogenesis, 2 Laboratory of the Molecular Biology of B Cells, and 3 Department of Cancer Biology, Institut de Génétique et de Biologie Moléculaire et Cellulaire, 67400 Illkirch, France
4 Institut National de la Santé et de la Recherche Médicale U964, 67400 Illkirch, France
5 Centre National de la Recherche Scientifique UMR7104, 67400 Illkirch, France
6 Université de Strasbourg, 67000 Strasbourg, France

CORRESPONDENCE Susan Chan: scpk{at}igbmc.fr OR Philippe Kastner: scpk{at}igbmc.fr

Class switch recombination (CSR) allows the humoral immune response to exploit different effector pathways through specific secondary antibody isotypes. However, the molecular mechanisms and factors that control immunoglobulin (Ig) isotype choice for CSR are unclear. We report that deficiency for the Ikaros transcription factor results in increased and ectopic CSR to IgG2b and IgG2a, and reduced CSR to all other isotypes, regardless of stimulation. Ikaros suppresses active chromatin marks, transcription, and activation-induced cytidine deaminase (AID) accessibility at the {gamma}2b and {gamma}2a genes to inhibit class switching to these isotypes. Further, Ikaros directly regulates isotype gene transcription as it directly binds the Igh 3' enhancer and interacts with isotype gene promoters. Finally, Ikaros-mediated repression of {gamma}2b and {gamma}2a transcription promotes switching to other isotype genes by allowing them to compete for AID-mediated recombination at the single-cell level. Thus, our results reveal transcriptional competition between constant region genes in individual cells to be a critical and general mechanism for isotype specification during CSR. We show that Ikaros is a master regulator of this competition.


M. Sellars’s present address is Molecular Pathogenesis Program, The Helen L. and Martin S. Kimmel Center for Biology and Medicine at the Skirball Institute for Biomolecular Medicine, New York University School of Medicine, New York, NY 10016.

Abbreviations used: 3C, chromosome conformation capture; AcH3, histone H3 acetylation; AID, activation-induced cytidine deaminase; ChIP, chromatin immunoprecipitation; CSR, class switch recombination; DSB, double-stranded DNA break; GLT, germline transcript; HDAC, histone deacetylase; HS, hypersensitive; I, intronic; NGFR, nerve growth factor receptor; qPCR, quantitative PCR; S, switch; SC, single cell.

© 2009 Sellars et al.
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS